Ra Capital Management, L.P. Buys 101,462 Shares of Climb Bio (NASDAQ:CLYM) Stock

Climb Bio, Inc. (NASDAQ:CLYM) Director Ra Capital Management, L.P. acquired 101,462 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average cost of $2.86 per share, for a total transaction of $290,181.32. Following the transaction, the director owned 3,396,318 shares of the company’s stock, valued at $9,713,469.48. This represents a 3.08% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, December 11th, Ra Capital Management, L.P. bought 213,099 shares of Climb Bio stock. The stock was purchased at an average price of $2.18 per share, with a total value of $464,555.82.

Climb Bio Stock Performance

CLYM stock opened at $4.62 on Wednesday. Climb Bio, Inc. has a one year low of $1.05 and a one year high of $4.82. The firm has a market cap of $314.99 million, a price-to-earnings ratio of -6.08 and a beta of -0.06. The firm has a 50-day simple moving average of $2.03 and a two-hundred day simple moving average of $1.83.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, equities analysts predict that Climb Bio, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Peapod Lane Capital LLC lifted its stake in Climb Bio by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 561,866 shares of the company’s stock valued at $1,129,000 after acquiring an additional 6,199 shares during the period. ADAR1 Capital Management LLC raised its holdings in shares of Climb Bio by 11.9% during the third quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock worth $268,000 after purchasing an additional 14,210 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Climb Bio during the third quarter worth $29,000. AQR Capital Management LLC acquired a new position in Climb Bio during the first quarter valued at $27,000. Finally, UBS Group AG boosted its holdings in Climb Bio by 6.0% in the third quarter. UBS Group AG now owns 405,404 shares of the company’s stock valued at $815,000 after purchasing an additional 22,922 shares during the last quarter. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CLYM. BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of Climb Bio in a report on Thursday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, October 8th. William Blair assumed coverage on shares of Climb Bio in a report on Thursday, October 16th. They set an “outperform” rating on the stock. HC Wainwright started coverage on shares of Climb Bio in a research report on Monday, October 13th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Climb Bio from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.